Citicoline IV Dose in Stroke
Citicoline is NOT recommended for acute ischemic stroke treatment, as the highest quality evidence demonstrates no efficacy, and it is not included in current stroke guidelines.
Evidence Against Citicoline Use
The most definitive evidence comes from the ICTUS trial 1, a large international randomized controlled trial (2298 patients) that was stopped for futility. This study used 1000 mg IV every 12 hours for 3 days, then oral continuation for 6 weeks, and found no benefit on functional recovery (OR 1.03,95% CI 0.86-1.25; p=0.364). This represents the highest quality evidence available and directly contradicts the use of citicoline in acute stroke.
Guideline Position
Neither the 2018 AHA/ASA guidelines 2 nor the 2015 focused update 3 mention citicoline as a treatment option for acute ischemic stroke. The guidelines focus exclusively on:
- IV alteplase (r-tPA) as the mainstay of early treatment
- Endovascular thrombectomy for large vessel occlusions
- Supportive care (blood pressure management, temperature control, glucose management)
The complete absence of citicoline from these authoritative guidelines, combined with the negative ICTUS trial, indicates it should not be used in clinical practice.
Why Earlier Studies Were Misleading
While some smaller studies suggested benefit 4 using doses of 500 mg IV daily for 7 days, and another study 5 used 2000 mg daily IV for 12-14 days, these were either uncontrolled or had significant methodological limitations. A more recent randomized trial 6 using 1 gram IV twice daily for 3 days also showed no significant benefit, confirming the ICTUS findings.
Critical Pitfall
The FDA drug label information provided 7 refers to simethicone (an anti-gas medication), not citicoline, and is completely irrelevant to stroke treatment. This highlights the importance of verifying drug information sources.
Bottom Line
Do not use citicoline for acute ischemic stroke. Focus instead on proven therapies: rapid IV thrombolysis with alteplase (0.9 mg/kg, max 90 mg) within 4.5 hours and endovascular thrombectomy for eligible patients with large vessel occlusions, as recommended by current AHA/ASA guidelines 2, 3.